Join our daily newsletter At The Bell to receive exclusive market insights
- Acrux (ACR) and its partner, Padagis, launch a prilocaine and lidocaine cream product in the United States
- The cream is used as a topical anaesthetic on the skin for numbing or as a pre-treatment for infiltration anaesthesia
- The company says it’s pleased to partner with Padagis for a second time to launch this high-volume product in the US
- Acrux shares are up 7.14 per cent to trade at 7.5 cents at 10:51 am AEDT
Acrux (ACR) and its partner, Padagis, have launched a prilocaine and lidocaine cream product in the United States
The cream is an AM-rated generic version of Emla Cream, used as a topical anaesthetic on normal intact skin to numb it or cause loss of feeling. It can also be used on genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia.
“We are pleased to partner with Padagis to launch this high-volume product in the United States,” Acrux CEO and Managing Director Michael Kotsanis said.
“Padagis is one of the leading generic companies in the United States, and we are excited to work with them on a second product.”
Padagis is a provider of extended topical and other specialty pharmaceuticals to its primary markets of the United States and Israel.
“At a time when other organisations are ceasing investment into generic products, this launch demonstrates our commitment to bringing, high quality, specialised, affordable products to patients and customers nationwide,” Padagis President and Chief Executive Officer Sharon Kochan commented.
“The Padagis team values the collaboration with Acrux and leveraged Acrux’s development expertise and our commercial platform and leadership in the topical space with the overall result of delivering this important product to the market.”
Acrux shares were up 7.14 per cent to trade at 7.5 cents at 10:51 am AEDT.
